Joseph G. Pressey · Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors
Follow
Article1 min read·Published Jul 2026

Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jul 2026 · 1 min read

In brief

In brief

This retrospective case series reports real-world outcomes of nirogacestat therapy in 11 young adult patients with desmoid tumors over 14 months. Results showed 88% achieved tumor volume reduction, 90% experienced rapid pain improvement, with manageable toxicities including diarrhea and ovarian dysfunction in this FDA-approved gamma secretase inhibitor treatment.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Background: With a peak incidence in young adulthood, desmoid tumors (DTs) often cause pain, loss of function, and diminished quality of life. On the basis of findings from the Phase III desmoid fibromatosis (DeFi) trial, the selective gamma secretase inhibitor nirogacestat was approved by the US Food and Drug Administration (FDA) in November 2023 for the treatment of patients with DT. Methods: A retrospective, single-institution chart review of patients with DT who initiated nirogacestat therapy over a 14-month period was undertaken. Measured real-world outcomes included radiographic tumor response, patient-reported pain, and toxicities attributable to nirogacestat. Results: Eleven young adult (YA) patients with DT who received nirogacestat were identified for the study. The median patient age was 26 years. The median duration of therapy at the time of the study was 8 months. RECIST responses included one patient with a partial response (PR), eight with stable disease (SD), and two were deemed radiologically inevaluable. Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in magnetic resonance imaging (MRI) T2-weighted signal intensity. Nine out of 10 patients who presented with pain (90%) reported rapid improvement. The most common toxicities included diarrhea, nausea, rash, and ovarian dysfunction. Discontinuation of nirogacestat was necessary in one patient due to severe diarrhea. Out of nine female patients, two elected to

Statements in this article

  1. Desmoid tumors have a peak incidence in young adulthood and often cause pain, loss of function, and diminished quality of life.

    EstablishedBackground
  2. Nirogacestat, a selective gamma secretase inhibitor, was approved by the US Food and Drug Administration in November 2023 for the treatment of patients with desmoid tumors based on findings from the Phase III DeFi trial.

    EstablishedBackground
  3. The median patient age in this series was 26 years.

    ResearchResults
  4. The median duration of nirogacestat therapy at the time of the study was 8 months.

    ResearchResults
  5. RECIST responses included one patient with a partial response, eight with stable disease, and two were deemed radiologically inevaluable.

    ResearchResults
  6. Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in MRI T2-weighted signal intensity.

    ResearchResults
  7. Nine out of 10 patients who presented with pain (90%) reported rapid improvement.

    ResearchResults
  8. The most common toxicities of nirogacestat included diarrhea, nausea, rash, and ovarian dysfunction.

    ResearchResults
  9. Discontinuation of nirogacestat was necessary in one patient due to severe diarrhea.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.